Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › NT5C2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia

NT5C2 inhibitors for the treatment of chemotherapy-resistant acute lymphoblastic leukemia

US Patent 12377107 · Granted Aug 5, 2025

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum 2025
Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum 2025
Compounds, compositions, and methods for modulating ferroptosis and treating exc2021
Small molecule ferroptosis inducers2021
Compounds, compositions, and methods for modulating ferroptosis and treating exc2020
Compounds, compositions, and methods for modulating ferroptosis and treating exc2019
Compounds, compositions, and methods for modulating ferroptosis and treating exc2019
Triazine compounds as PI3 kinase and mTOR inhibitors2018
Carbonyl erastin analogs and their use2018
Multivalent RAS binding compounds2018
Pyridopyrimidine or pyrimidopyrimidine compound, prepration method, pharmaceutic2017
Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use2017